Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges

Absolute benefits of antiplatelet therapy with aspirin on serious vascular events (nonfatal myocardial infarction, nonfatal stroke, or death from vascular causes) in different groups of high-risk patients. The size of the absolute benefit is expressed by the number of serious vascular events avoided by long-term (2–3 years) aspirin therapy per 1000 patients. Based on analysis of data from the Antithrombotic Trialists’ Collaboration (33).